1
|
Fakher HE, El Gazzar NM, Mabrouk MM, Nada DW. The study of serum muscarinic acetylcholine receptor subtype 3 (m3AChR)-Specific autoantibodies level in rheumatoid arthritis patients with secondary sjogren syndrome. BMC Rheumatol 2023; 7:45. [PMID: 38105265 PMCID: PMC10726573 DOI: 10.1186/s41927-023-00368-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Accepted: 11/28/2023] [Indexed: 12/19/2023] Open
Abstract
BACKGROUND Dry eyes and mouth are symptoms of Sjogren syndrome, which can occur on its own and be referred to as primary Sjogren syndrome or in conjunction with other rheumatic diseases like rheumatoid arthritis and be referred to as secondary Sjogren syndrome. Anti-muscarinic type 3 receptors have been linked to neurological issues as well as secretory dysfunction in Sjogren patients. Consequently, the purpose of this study is to determine the serum level of muscarinic acetylcholine receptor subtype 3 (m3AChR)-specific autoantibodies in rheumatoid arthritis (RA) patients and evaluate its relationship to disease activity, functional disability, and to study its role in the development of secondary Sjogren syndrome manifestations in those patients. METHODS In this cross-sectional study, 30 RA patients with secondary Sjogren syndrome signs and 30 RA patients without secondary Sjogren syndrome manifestations were included, along with 30 healthy volunteers who were aged, and sex matched as controls. All participants underwent thorough clinical examination, evaluation of disease activity using the DAS28 score, assessment of functional status using the modified health assessment questionnaire (MHAQ), and evaluation of the serum level of (m3AChR) by (ELISA). RESULTS When compared to RA patients without secondary Sjogren syndrome and healthy controls (20.09 ± 4.24, 18.36 ± 3.59 ng/ml respectively), the serum level of m3AChR antibodies among 30 RA patients with secondary Sjogren syndrome considerably increased (mean 25.98 ± 4.81 ng/ml).Analysis of the m3AChR's (ROC)-curve revealed that the three groups under study differed significantly (P < 0.001), with the AUC (0.806), cutoff (> 22.63ng/ml), sensitivity (73.33%), and specificity (86.67%) all exceeding the threshold. Additionally, there was a significant positive connection between the serum level of m3AChR and the following variables (P < 0.05): DAS scores, MHAQ score, number of tender & swollen joints, and acute phase reactants. CONCLUSION Autoantibodies against m3AChR may be one of the serum components involved in the pathophysiology of secondary Sjogren syndrome in RA patients, and because of their high sensitivity and specificity, they can be utilized as a diagnostic marker in these individuals.
Collapse
Affiliation(s)
- Hagar Elsayed Fakher
- Department of Rheumatology, Rehabilitation & Physical Medicine, Faculty of Medicine, Tanta University, El-Gharbia Governorate, Tanta City, Egypt
| | - Nagat Mohammed El Gazzar
- Department of Rheumatology, Rehabilitation & Physical Medicine, Faculty of Medicine, Tanta University, El-Gharbia Governorate, Tanta City, Egypt
| | - Maaly Mohamed Mabrouk
- Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta City, El- Gharbia Governorate, Egypt
| | - Doaa Waseem Nada
- Department of Rheumatology, Rehabilitation & Physical Medicine, Faculty of Medicine, Tanta University, El-Gharbia Governorate, Tanta City, Egypt.
| |
Collapse
|
3
|
Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry. Rheumatol Int 2020; 40:1239-1248. [PMID: 32449040 PMCID: PMC7316680 DOI: 10.1007/s00296-020-04602-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 05/05/2020] [Indexed: 02/07/2023]
Abstract
The objective of this study was to compare rheumatoid arthritis (RA) disease activity and patient-reported outcomes (PROs) in a national sample of patients with RA with/without Sjögren's syndrome (SS). Adults with RA from a large observational US registry (Corrona RA) with known SS status between 22 April 2010 and 31 July 2018 and a visit 12 (± 3) months after index date were identified (n = 36,256/52,757). SS status: determined from a yes/no variable reported at enrolment into the Corrona RA registry and follow-up visits. Index date: date that SS status was recorded (yes/no). Patients received biologic or targeted synthetic disease-modifying antirheumatic drugs as part of standard care. Patients with RA only were followed for ≥ 12 months to confirm the absence of SS. Patients were frequency- and propensity-score matched (PSM) 1:1 and stratified by disease duration and treatment response-associated variables, respectively. Clinical Disease Activity Index (CDAI) and PROs 12 months after index visit were compared in patients with and without SS. Baseline characteristics in 283 pairs of PSM patients were balanced. Mean change in CDAI score was numerically lower in patients with RA and SS than patients with RA only (8.8 vs 9.3). Reductions in PROs of pain, fatigue and stiffness were two- to threefold lower for patients with RA and SS versus RA only. Reductions in RA disease activity and RA-related PROs were lower in patients with RA and SS versus those with RA only. Our data indicate that SS adds to treatment challenges; physicians may wish to consider SS status when managing patients with RA.
Collapse
Affiliation(s)
- Leslie R. Harrold
- Corrona, LLC, 1440 Main Street, Suite 310, Waltham, MA 02451 USA
- University of Massachusetts Medical School, Worcester, MA USA
| | - Ying Shan
- Corrona, LLC, 1440 Main Street, Suite 310, Waltham, MA 02451 USA
| | - Sabrina Rebello
- Corrona, LLC, 1440 Main Street, Suite 310, Waltham, MA 02451 USA
| | - Neil Kramer
- Institute for Rheumatic & Autoimmune Diseases, Overlook Medical Center, Summit, NJ USA
| | | | | | | | - Joel M. Kremer
- Albany Medical College and the Center for Rheumatology, Albany, NY USA
| | - Elliot D. Rosenstein
- Institute for Rheumatic & Autoimmune Diseases, Overlook Medical Center, Summit, NJ USA
| |
Collapse
|
6
|
Rodríguez-Pomar C, Pintor J, Colligris B, Carracedo G. Therapeutic inhibitors for the treatment of dry eye syndrome. Expert Opin Pharmacother 2017; 18:1855-1865. [PMID: 29115899 DOI: 10.1080/14656566.2017.1403584] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
INTRODUCTION Dry eye disease (DED), defined as a multifactorial disease of tears and ocular surface, results in symptoms of discomfort, ocular irritation, visual disturbance and tear film instability. This syndrome is accompanied of ocular surface inflammation and it is produced by a deficient activity of the lacrimal functional unit. In addition, it is associated with systemic autoimmune diseases such as Sjögren´s Syndrome, rheumatoid arthritis, systemic lupus erythematosus and some drug administration. The treatment of dry eye disease is based on the typical signs and symptoms of dry eye, which are associated with hyperosmolarity, ocular surface inflammation, discomfort, visual disturbance, and tear film instability. Areas covered: This review is focused on synthetic drugs currently used in clinical practice, from phase III development onwards to treat the ocular surface signs and symptoms of dry eye disease. Expert opinion: The multifactorial disease and the lack of correlation between signs and symptoms imply that not all the pharmacological approaches will be successful for dry eye. The correct design of the clinical trials, with appropriate endpoints, and the type of dry eye under study are complicated but mandatory. The anti-inflammatory and secretagogues drugs are both the main compounds to currently treat the dry eye disease.
Collapse
Affiliation(s)
- Candela Rodríguez-Pomar
- a Department of Optics II (Optometry and Vision), Faculty of Optic and Optometry , Universidad Complutense de Madrid , Madrid , Spain.,b Ocupharm Group Research; Department of Biochemistry and Molecular Biology IV, Faculty of Optic and Optometry , Universidad Complutense de Madrid , Madrid , Spain
| | - Jesus Pintor
- b Ocupharm Group Research; Department of Biochemistry and Molecular Biology IV, Faculty of Optic and Optometry , Universidad Complutense de Madrid , Madrid , Spain
| | - Basilio Colligris
- b Ocupharm Group Research; Department of Biochemistry and Molecular Biology IV, Faculty of Optic and Optometry , Universidad Complutense de Madrid , Madrid , Spain
| | - Gonzalo Carracedo
- a Department of Optics II (Optometry and Vision), Faculty of Optic and Optometry , Universidad Complutense de Madrid , Madrid , Spain.,b Ocupharm Group Research; Department of Biochemistry and Molecular Biology IV, Faculty of Optic and Optometry , Universidad Complutense de Madrid , Madrid , Spain
| |
Collapse
|
8
|
Lins E Silva M, Carvalho CN, Carvalho ADAT, Leão JC, Duarte ALP, Gueiros LA. Effect of Xerostomia on the Functional Capacity of Subjects with Rheumatoid Arthritis. J Rheumatol 2016; 43:1795-1800. [PMID: 27585681 DOI: 10.3899/jrheum.151211] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2016] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To evaluate the intensity of xerostomia and hyposalivation in subjects with rheumatoid arthritis (RA) as well as the effects of these conditions on functional incapacity and disease activity. METHODS The study sample comprised 236 individuals of both sexes who had RA. All the individuals were submitted to clinical evaluation and unstimulated sialometry. Functional capacity was determined by using the Health Assessment Questionnaire (HAQ), xerostomia was assessed using the Xerostomia Inventory, and disease activity was evaluated with the 28-joint Disease Activity Score (DAS28). The effect of Sjögren syndrome (SS) was analyzed, and the sample was divided into 2 groups: RA (191 subjects) and RA/SS (45 subjects). RESULTS The Xerostomia Inventory showed positive and significant correlation with fatigue (r = 0.243; p < 0.0001), number of painful joints (r = 0.218; p = 0.001), HAQ (r = 0.279; p < 0.0001), and DAS28 (r = 0.156; p < 0.0001). On regression analysis, both xerostomia (OR 3.89, 95% CI 1.84-8.23, p < 0.001) and DAS28 (for severe disease activity: OR 13.26, 95% CI 3.15-55.79, p < 0.001) showed influence on functional incapacity. Forty-five individuals (19.1%) presented with secondary SS, and having this diagnosis was not associated with disease activity or functional capacity. CONCLUSION Xerostomia demonstrated an adverse effect on quality of life of subjects with RA, being associated with a reduction in functional capacity. In this clinical setting, xerostomia can be monitored as a marker of worse clinical evolution.
Collapse
Affiliation(s)
- Marília Lins E Silva
- From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.M. Lins e Silva, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; C.N. Carvalho, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.A. Carvalho, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; J.C. Leão, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.L. Duarte, DDS, MSc, PhD, Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco; L.A. Gueiros, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco
| | - Camila Nunes Carvalho
- From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.M. Lins e Silva, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; C.N. Carvalho, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.A. Carvalho, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; J.C. Leão, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.L. Duarte, DDS, MSc, PhD, Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco; L.A. Gueiros, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco
| | - Alessandra de Albuquerque Tavares Carvalho
- From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.M. Lins e Silva, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; C.N. Carvalho, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.A. Carvalho, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; J.C. Leão, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.L. Duarte, DDS, MSc, PhD, Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco; L.A. Gueiros, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco
| | - Jair Carneiro Leão
- From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.M. Lins e Silva, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; C.N. Carvalho, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.A. Carvalho, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; J.C. Leão, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.L. Duarte, DDS, MSc, PhD, Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco; L.A. Gueiros, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco
| | - Angela Luzia Pinto Duarte
- From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.M. Lins e Silva, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; C.N. Carvalho, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.A. Carvalho, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; J.C. Leão, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.L. Duarte, DDS, MSc, PhD, Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco; L.A. Gueiros, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco
| | - Luiz Alcino Gueiros
- From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.M. Lins e Silva, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; C.N. Carvalho, DDS, MSc, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.A. Carvalho, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; J.C. Leão, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco; A.L. Duarte, DDS, MSc, PhD, Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco; L.A. Gueiros, DDS, MSc, PhD, Oral Medicine Unit, Department of Clinical and Preventive Dentistry, Federal University of Pernambuco.
| |
Collapse
|